Expression and Significance of S1PR1 in Primary Testicular Diffuse Large B-cell Lymphoma Tissue

doi:10.12114/j.issn.1007-9572.2019.00.315

Abstract

Abstract: Background　 Studies have shown that sphingosine-1-phosphate receptor 1 （S1PR1） can be used as a drug target for the treatment of various diseases.Primary testicular diffuse large B-cell lymphoma （PT-DLBCL） is an extranodal lymphoma with a low incidence but a high degree of invasiveness.The overall prognosis is very poor after treating by existing therapies and it is urgent to find new therapeutic targets.Objective　To explore the expression of S1PR1 in pathological tissue of PT-DLBCL，and analyze its relationship with the prognosis of PT-DLBCL，then to find out the potential of S1P/S1PR1 as a therapeutic target for this disease.Methods　 From Yunnan Cancer Hospital，37 cases of PT-DLBCL and 37 cases of diffuse large B-cell lymphoma （DLBCL） were randomly recruited from May 1994 to March 2016.Immunohistochemistry was used to detect the expressional level of S1PR1 in paraffin wax block with the embedded PT-DLBCL and DLBCL tissues.Clinical data of PT-DLBCL cases were reviewed，and relationship of S1PR1 expressional level with the prognosis of PT-DLBCL was analyzed.Results　 S1PR1 expression level was negative in 45.8%（n=17） of the PT-DLBCL cases，and in 70.3%（n=26） of the DLBCL cases.The prevalence of positive S1PR1 expression level was 54.1%（n=20） in the PT-DLBCL cases，and 29.7% （n=11） in the DLBCL cases，showing a significant difference（χ2=4.497，P=0.034）．The median overall survival （OS） was （21.9±4.6） months and the median progression-free survival （PFS） was （10.1±2.3） months in 20 PT-DLBCL patients with S1PR1 positive expression，and in 17 PT-DLBCL patients with S1PR1 negative expression，the median OS was （71.9±9.6） months and the median PFS was （64.6±10.9）months.3 and 5 years OS rates（15.0% and 10.0%） in the positive expression of S1PR1 were lower than those in the negative expression of S1PR1 （52.9% and 35.3%）（χ2=10.971，P=0.001）．3 and 5 years PFS rates（5.0% and 0） in the positive expression of S1PR1 were lower than those in the negative expression of S1PR1 （35.3% and 23.5%）（χ2=15.833，P<0.001）.Conclusion　The expression rate of S1PR1 in PT-DLBCL was higher than that in intranodal DLBCL，and its expression was related to the prognosis of PT-DLBCL.S1P/S1PR1 has the potential as a therapeutic target for the disease.

Key words: Lymphoma, large B-call, diffuse；Neoplasms, multiple primary；Sphingosine-1-phosphate receptor 1；Primary testicular diffuse large B-cell lymphoma；Prognosis

摘要： 背景　国内外研究已表明鞘氨醇-1-磷酸受体1（S1PR1）可作为多种疾病治疗的药物靶点。原发性睾丸弥漫大B细胞淋巴瘤（PT-DLBCL）为发病率较低的结外淋巴瘤，但侵袭能力强，应用现有的手段治疗后整体预后极差，亟须寻找新的治疗靶点。目的　了解S1PR1在PT-DLBCL病理组织中的表达情况，分析S1PR1的表达与PT-DLBCL预后的关系，探讨鞘氨醇-1-磷酸（S1P）/S1PR1作为该病治疗靶点的潜力。方法　收集1994年5月—2016年3月云南省肿瘤医院PT-DLBCL病理蜡块37例，随机选取普通结内弥漫大B细胞淋巴瘤（DLBCL）病理蜡块37例，通过免疫组化法比较S1PR1在PT-DLBCL和普通结内DLBCL组织中的表达差异。收集37例PT-DLBCL患者的临床资料，分析S1PR1的表达与患者预后的关系。结果　37例PT-DLBCL组织中，S1PR1表达阳性20例（54.1%）、阴性17例（45.8%）。37例普通结内DLBCL组织中，S1PR1表达阳性11例（29.7%）、阴性26例（70.3%）。PT-DLBCL组织中S1PR1阳性表达率高于普通结内DLBCL组织（χ2=4.497，P=0.034）。37例PT-DLBCL患者中，20例S1PR1阳性表达者中位总生存期（OS）为（21.9±4.6）个月、中位无进展生存期（PFS）为（10.1±2.3）个月，17例S1PR1阴性表达者中位OS为（71.9±9.6）个月、中位PFS为（64.6±10.9）个月。S1PR1阳性表达者3、5年总生存率（15.0%、10.0%）低于S1PR1阴性表达者3、5年总生存率（52.9%、35.3%）（χ2=10.971，P=0.001）；S1PR1阳性表达者3、5年无进展生存率（5.0%、0）低于S1PR1阴性表达者3、5年无进展生存率（35.3%、23.5%）（χ2=15.833，P<0.001）。结论　S1PR1在PT-DLBCL中阳性表达率较普通结内DLBCL高，且其表达率高低与PT-DLBCL预后情况相关，S1P/S1PR1具有作为该病治疗靶点的潜力。

关键词: 淋巴瘤, 大B细胞, 弥漫性, 肿瘤, 多原发性, 鞘氨醇-1-磷酸受体1, 原发性睾丸弥漫大B细胞淋巴瘤, 预后

LIAO Yedan,LI Mei,CHEN Yun, et al. Expression and Significance of S1PR1 in Primary Testicular Diffuse Large B-cell Lymphoma Tissue　[J]. Chinese General Practice, 2019, 22(29): 3576-3579. DOI: 10.12114/j.issn.1007-9572.2019.00.315.
廖冶丹,李梅,陈芸等. 鞘氨醇-1-磷酸受体1在原发性睾丸弥漫大B细胞淋巴瘤组织中的表达及意义[J]. 中国全科医学, 2019, 22(29): 3576-3579. DOI: 10.12114/j.issn.1007-9572.2019.00.315.

References

［1］YATOMI Y，OHMORI T，RILE G，et al．Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells［J］．Blood，2000，96（10）：3431-3438.
［2］MACEYKA M，HARIKUMAR K B，MILSTIEN S，et al．Sphingosine-1-phosphate signaling and its role in disease［J］．Trends Cell Biol，2012，22（1）：50-60．
［3］LIANG J，NAGAHASHI M，KIM E Y，et al．Sphingosine-1-phosphate links persistent STAT3 activation，chronic intestinal inflammation，and development of colitis-associated cancer［J］．Cancer Cell，2013，23（1）：107-120．
［4］HARDEE J，OUYANG Z Q，ZHANG Y P，et al．STAT3 targets suggest mechanisms of aggressive tumorigenesis in diffuse large B-cell lymphoma［J］．G3 （Bethesda），2013，3（12）：2173-2185．DOI：10.1534/g3.113.007674.
［5］DENG L，XU-MONETTEZ Y，LOGHAVI S，et al．Primary testicular diffuse large B-cell lymphoma displaysdistinct clinical and biological features for treatment failure inrituximab era：a report from the International PTL consortium［J］．Leukemia，2016，30（2）：361-372．DOI：10.1038/leu.2015.237.
［6］PYNE N J，PYNE S.Sphingosine 1-phosphate and cancer［J］．Nat Rev Cancer，2010，10（7）：489-503．DOI：10.1038/nrc2875.
［7］WELCH S P，SIM-SELLEY L J，SELLEY D E．Sphingosine-1-phosphate receptors as emerging targets for treatment of pain［J］．Biochem Pharmacol，2012，84（12）：1551-1562．
［8］LANKADASARI M B，APARNA J S，MOHAMMED S，et al．Targeting S1PR1/STAT3 loop abrogates desmoplasia and chemosensitizes pancreatic cancer to gemcitabine［J］．Theranostics，2018，8（14）：3824-3840．
［9］FDA.Label approved on 09/21/2010 for GILENYA，NDA no 022527［EB/OL］．（2010-09-21）［2018-10-11］．http：//www.Accessdata.fda.gov /drugsatfda_docs/label/2010/022527s000lbl.
［10］MENON M P，PITTALUGA S，JAFFE E S.The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification［J］．Cancer J，2012，18（5）：411-420．DOI：10.1097/PPO.0b013e31826aee97.
［11］AHMAD S S，IDRIS S F，FOLLOWS G A，et al．Primary testicular lymphoma［J］．Clin Oncol（R Coll Radiol），2012，24（5）：358-365．DOI：10.1016/j.clon.2012.02.005.
［12］XU H，YAO F.Primary testicular lymphoma：a SEER analysis of 1，169 cases［J］．Oncol Lett，2019，17（3）：3113-3124．
［13］GOEL S，SACHDEV R，MOHAPATRA I，et al．Unusually aggressive primary testicular diffuse large B cell lymphoma with post therapy extensive metastasis［J］．J Clin Diagn Res，2016，10（7）：ED01-2．DOI：10.7860/JCDR/2016/17441.8074.
［14］WASIK A M，WU C L，MANSOURI L，et al．Clinical and functional impact of recurrent S1PR1 mutations in mantle cell lymphoma［J］．Blood Adv，2018，2（6）：621-625．
［15］PATRUSSI L，CAPITANI N，MARTINI V，et al．Enhanced chemokine receptor recycling and impaired S1P1 expression promote leukemic cell infiltration of lymph nodes in chronic lymphocytic leukemia［J］．Cancer Res，2015，75（19）：4153-4163．
［16］MIDDLE S，COUPLAND S E，TAKTAK A，et al．Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors，sphingosine-1-phosphate receptors and integrins［J］．Exp Hematol Oncol，2015，4（1）：10．
［17］NISHIMURA H，AKIYAMA T，MONOBE Y，et al．Expression of sphingosine-1-phosphate receptor 1 in mantle cell lymphoma［J］．Mod Pathol，2010，23（3）：439-449．

[1]	Zhenqiang REN, Yi GUAN, Fei PENG, Yongtao SHI, Mengyang YU. Marital Status and Prognosis in Patients with Primary Central Nervous System Lymphoma: a Propensity Score Matching-based Study [J]. Chinese General Practice, 2022, 25(19): 2356-2362.
[2]	Xiangliu OUYANG, Bei GAO, Yanbin WANG, Liyun LIU, Cheng GU, Lichun ZHENG. Ultrasonographic Analysis of Primary Thyroid Lymphoma [J]. Chinese General Practice, 2022, 25(15): 1869-1874.
[3]	YANG Jingshi，ZOU Liqun. New Progression in Influencing Factors and Risk Prediction Models for Lymphoma-associated Venous Thromboembolism　 [J]. Chinese General Practice, 2021, 24(23): 2992-2997.
[4]	ZHAO Tongde，XU Yamei. Lymphoma with thrombotic thrombocytopenic purpura as the first symptom：report of two cases and literature review [J]. Chinese General Practice, 2020, 23(21): 2727-2730.
[5]	LIU Fan，ZHAO Yu，PAN Xinyu，FU Yao，YU Jianbo. Application of In Vivo Imaging Technique in the Early Detection of NK/T Cell Lymphoma　 [J]. Chinese General Practice, 2019, 22(30): 3689-3693.
[6]	HUANG Shen-an，QIAN Xia，ZHANG Li-hua，SHANG Hong-wei，XIONG Ping，FANG Nian. Efficacy of Gastroscopic Submucosal Dissection in the Adjuvant Diagnosis and Treatment of Primary Gastric Lymphoma [J]. Chinese General Practice, 2018, 21(23): 2818-2822.